tiprankstipranks
Trending News
More News >
Crispr Therapeutics (GB:0VRQ)
:0VRQ
UK Market

Crispr Therapeutics AG (0VRQ) Share Forecast & Price Target

Compare
5 Followers
See the Price Targets and Ratings of:

0VRQ Analyst Ratings

Moderate Buy
18Ratings
13 Buy
5 Hold
0 Sell
Based on 18 analysts giving stock ratings to
Crispr
Therapeutics AG
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

0VRQ Stock 12 Month Forecast

Average Price Target

$68.38
▲(78.35% Upside)
Based on 18 Wall Street analysts offering 12 month price targets for Crispr Therapeutics AG in the last 3 months. The average price target is $68.38 with a high forecast of $105.00 and a low forecast of $35.00. The average price target represents a 78.35% change from the last price of $38.34.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"32":"$32","69":"$69","106":"$106","50.5":"$50.5","87.5":"$87.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":105,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$105.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":68.38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$68.38</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":35,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$35.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[32,50.5,69,87.5,106],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2024","6":"Nov<br/>2024","9":"Feb<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,37.548,42.736615384615384,47.92523076923077,53.113846153846154,58.30246153846154,63.491076923076925,68.6796923076923,73.8683076923077,79.05692307692308,84.24553846153846,89.43415384615385,94.62276923076922,99.81138461538461,{"y":105,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,37.548,39.91969230769231,42.291384615384615,44.66307692307692,47.03476923076923,49.406461538461535,51.77815384615384,54.149846153846156,56.521538461538455,58.89323076923077,61.26492307692307,63.63661538461538,66.00830769230768,{"y":68.38,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,37.548,37.352000000000004,37.156,36.96,36.764,36.568,36.372,36.176,35.980000000000004,35.784,35.588,35.392,35.196,{"y":35,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":64.607,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.48,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.75,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.55,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.206,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.256,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.04,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.263,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.229,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.83,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.52,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.429,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.548,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$105.00Average Price Target$68.38Lowest Price Target$35.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
William Blair Analyst forecast on GB:0VRQ
Sami CorwinWilliam Blair
William Blair
Buy
Reiterated
05/20/25
Citi
$82
Buy
113.88%
Upside
Reiterated
05/19/25
Bank of America Securities Analyst forecast on GB:0VRQ
Alec StranahanBank of America Securities
Bank of America Securities
$79
Buy
106.05%
Upside
Reiterated
05/16/25
Barclays Analyst forecast on GB:0VRQ
Gena WangBarclays
Barclays
$56$42
Hold
9.55%
Upside
Reiterated
05/09/25
Truist Financial Analyst forecast on GB:0VRQ
Joon LeeTruist Financial
Truist Financial
Buy
Reiterated
05/08/25
BMO Capital Analyst forecast on GB:0VRQ
Kostas BiliourisBMO Capital
BMO Capital
$97$75
Buy
95.62%
Upside
Reiterated
05/08/25
Chardan Capital Analyst forecast on GB:0VRQ
Geulah LivshitsChardan Capital
Chardan Capital
$84$82
Buy
113.88%
Upside
Reiterated
05/07/25
Clear Street Analyst forecast on GB:0VRQ
William MaughanClear Street
Clear Street
$45
Buy
17.37%
Upside
Upgraded
05/07/25
Evercore ISI Analyst forecast on GB:0VRQ
Liisa BaykoEvercore ISI
Evercore ISI
$99
Buy
158.22%
Upside
Reiterated
05/07/25
Citizens JMP Analyst forecast on GB:0VRQ
Silvan TuerkcanCitizens JMP
Citizens JMP
$86
Buy
124.31%
Upside
Reiterated
05/07/25
Needham Analyst forecast on GB:0VRQ
Gil BlumNeedham
Needham
$84$81
Buy
111.27%
Upside
Reiterated
05/07/25
Piper Sandler Analyst forecast on GB:0VRQ
Edward TenthoffPiper Sandler
Piper Sandler
$105
Buy
173.87%
Upside
Reiterated
05/07/25
RBC Capital Analyst forecast on GB:0VRQ
Luca IssiRBC Capital
RBC Capital
$38
Hold
-0.89%
Downside
Reiterated
05/07/25
H.C. Wainwright Analyst forecast on GB:0VRQ
Mitchell KapoorH.C. Wainwright
H.C. Wainwright
$65
Buy
69.54%
Upside
Reiterated
05/07/25
TD Cowen
$35
Hold
-8.71%
Downside
Reiterated
05/06/25
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
William Blair Analyst forecast on GB:0VRQ
Sami CorwinWilliam Blair
William Blair
Buy
Reiterated
05/20/25
Citi
$82
Buy
113.88%
Upside
Reiterated
05/19/25
Bank of America Securities Analyst forecast on GB:0VRQ
Alec StranahanBank of America Securities
Bank of America Securities
$79
Buy
106.05%
Upside
Reiterated
05/16/25
Barclays Analyst forecast on GB:0VRQ
Gena WangBarclays
Barclays
$56$42
Hold
9.55%
Upside
Reiterated
05/09/25
Truist Financial Analyst forecast on GB:0VRQ
Joon LeeTruist Financial
Truist Financial
Buy
Reiterated
05/08/25
BMO Capital Analyst forecast on GB:0VRQ
Kostas BiliourisBMO Capital
BMO Capital
$97$75
Buy
95.62%
Upside
Reiterated
05/08/25
Chardan Capital Analyst forecast on GB:0VRQ
Geulah LivshitsChardan Capital
Chardan Capital
$84$82
Buy
113.88%
Upside
Reiterated
05/07/25
Clear Street Analyst forecast on GB:0VRQ
William MaughanClear Street
Clear Street
$45
Buy
17.37%
Upside
Upgraded
05/07/25
Evercore ISI Analyst forecast on GB:0VRQ
Liisa BaykoEvercore ISI
Evercore ISI
$99
Buy
158.22%
Upside
Reiterated
05/07/25
Citizens JMP Analyst forecast on GB:0VRQ
Silvan TuerkcanCitizens JMP
Citizens JMP
$86
Buy
124.31%
Upside
Reiterated
05/07/25
Needham Analyst forecast on GB:0VRQ
Gil BlumNeedham
Needham
$84$81
Buy
111.27%
Upside
Reiterated
05/07/25
Piper Sandler Analyst forecast on GB:0VRQ
Edward TenthoffPiper Sandler
Piper Sandler
$105
Buy
173.87%
Upside
Reiterated
05/07/25
RBC Capital Analyst forecast on GB:0VRQ
Luca IssiRBC Capital
RBC Capital
$38
Hold
-0.89%
Downside
Reiterated
05/07/25
H.C. Wainwright Analyst forecast on GB:0VRQ
Mitchell KapoorH.C. Wainwright
H.C. Wainwright
$65
Buy
69.54%
Upside
Reiterated
05/07/25
TD Cowen
$35
Hold
-8.71%
Downside
Reiterated
05/06/25
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Crispr Therapeutics AG

Which Analyst Should I Follow If I Want to Buy GB:0VRQ and Sell After:
1 Month
xxx
Success Rate
12/18 ratings generated profit
67%
Average Return
+9.43%
reiterated a xxx
rating 7 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +9.43% per trade.
3 Months
xxx
Success Rate
23/41 ratings generated profit
56%
Average Return
+12.30%
reiterated a xxx
rating 15 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 56.10% of your transactions generating a profit, with an average return of +12.30% per trade.
1 Year
Geulah LivshitsChardan Capital
Success Rate
18/41 ratings generated profit
44%
Average Return
+16.87%
reiterated a buy rating 15 days ago
Copying Geulah Livshits's trades and holding each position for 1 Year would result in 43.90% of your transactions generating a profit, with an average return of +16.87% per trade.
2 Years
xxx
Success Rate
14/41 ratings generated profit
34%
Average Return
+1.48%
reiterated a xxx
rating 15 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 34.15% of your transactions generating a profit, with an average return of +1.48% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0VRQ Analyst Recommendation Trends

Rating
Jan 25
Feb 25
Mar 25
Apr 25
May 25
Strong Buy
11
18
16
18
17
Buy
9
5
4
2
3
Hold
9
9
7
8
6
Sell
3
2
2
1
0
Strong Sell
0
0
0
0
0
total
32
34
29
29
26
In the current month, 0VRQ has received 20 Buy Ratings, 6 Hold Ratings, and 0 Sell Ratings. 0VRQ average Analyst price target in the past 3 months is 68.38.
Each month's total comprises the sum of three months' worth of ratings.

0VRQ Financial Forecast

0VRQ Earnings Forecast

Next quarter’s earnings estimate for 0VRQ is -$1.43 with a range of -$2.27 to -$0.93. The previous quarter’s EPS was -$1.58. 0VRQ beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 39.73% of the time in the same period. In the last calendar year 0VRQ has Outperformed its overall industry.
Next quarter’s earnings estimate for 0VRQ is -$1.43 with a range of -$2.27 to -$0.93. The previous quarter’s EPS was -$1.58. 0VRQ beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 39.73% of the time in the same period. In the last calendar year 0VRQ has Outperformed its overall industry.

0VRQ Sales Forecast

Next quarter’s sales forecast for 0VRQ is $6.26M with a range of $0.00 to $31.07M. The previous quarter’s sales results were $865.00K. 0VRQ beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 43.86% of the time in the same period. In the last calendar year 0VRQ has Outperformed its overall industry.
Next quarter’s sales forecast for 0VRQ is $6.26M with a range of $0.00 to $31.07M. The previous quarter’s sales results were $865.00K. 0VRQ beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 43.86% of the time in the same period. In the last calendar year 0VRQ has Outperformed its overall industry.

0VRQ Stock Forecast FAQ

What is GB:0VRQ’s average 12-month price target, according to analysts?
Based on analyst ratings, Crispr Therapeutics’s 12-month average price target is 68.38.
    What is GB:0VRQ’s upside potential, based on the analysts’ average price target?
    Crispr Therapeutics has 78.35% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Crispr Therapeutics a Buy, Sell or Hold?
          Crispr Therapeutics has a consensus rating of Moderate Buy, which is based on 13 buy ratings, 5 hold ratings and 0 sell ratings.
            What is Crispr Therapeutics’s share price target?
            The average share price target for Crispr Therapeutics is 68.38. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is $105.00 ,and the lowest forecast is $35.00. The average share price target represents 78.35% Increase from the current price of $38.34.
              What do analysts say about Crispr Therapeutics?
              Crispr Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 18 Wall Streets Analysts.
                How can I buy shares of Crispr Therapeutics?
                To buy shares of GB:0VRQ, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis